In vivo detection of succinate by magnetic resonance spectroscopy as a hallmark of SDHx mutations in paraganglioma

Clinical Cancer Research

Volumn 22, Issue 5, 2016, Pages 1120-1129

  Lussey Lepoutre, Charlotte ^a,b   Bellucci, Alexandre ^a,b   Morin, Aurélie ^a,b   Buffet, Alexandre ^a,b   Amar, Laurence ^a,b,c   Janin, Maxime ^b,d,e   Ottolenghi, Chris ^b,d,e   Zinzindohoué, Franck ^b,c   Autret, Gwennhael ^a,b   Burnichon, Nelly ^a,b,c   Robidel, Estelle ^a,b   Banting, Benjamin ^c   Fontaine, Sébastien ^c   Cuenod, Charles André ^a,b,c   Benit, Paule ^b,f   Rustin, Pierre ^b,f   Halimi, Philippe ^b,c   Fournier, Laure ^a,b,c   Gimenez Roqueplo, Anne Paule ^a,b,c   Favier, Judith ^a,b   Tavitian, Bertrand ^a,b,c   more..

^a PARIS CARDIOVASCULAR RESEARCH CENTER   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

^e INSERM   (France)

^f HÔPITAL ROBERT DEBRÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

SUCCINATE DEHYDROGENASE; SUCCINIC ACID; MEMBRANE PROTEIN; SDHA PROTEIN, HUMAN; SDHB PROTEIN, HUMAN; SDHC PROTEIN, HUMAN; SDHD PROTEIN, HUMAN; SUCCINATE DEHYDROGENASE (UBIQUINONE);

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHROMAFFIN CELL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE MUTATION; GERMLINE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MALE; MASS FRAGMENTOGRAPHY; MIDDLE AGED; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARAGANGLIOMA; PATHOGENICITY; PRIORITY JOURNAL; PROCESS DEVELOPMENT; PROCESS OPTIMIZATION; PROTEIN EXPRESSION; PROTON NUCLEAR MAGNETIC RESONANCE; SDHX GENE; SENSITIVITY AND SPECIFICITY; WILD TYPE; ANIMAL; DRUG SCREENING; GENETIC PREDISPOSITION; GENETICS; METABOLISM; PATHOLOGY; PHEOCHROMOCYTOMA;

ANIMALS; ELECTRON TRANSPORT COMPLEX II; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MEMBRANE PROTEINS; MICE; PARAGANGLIOMA; PHEOCHROMOCYTOMA; SUCCINATE DEHYDROGENASE; SUCCINIC ACID; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84962226011     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-1576     Document Type: Article

References (38)

1. Lenders JW, Duh QY, Eisenhofer G, Gimenez-Roqueplo AP, Grebe SK, Murad MH, et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2014;99: 1915-42.
2. Favier J, Amar L, Gimenez-Roqueplo AP. Paraganglioma and phaeochromocytoma: from genetics to personalized medicine. Nat Rev Endocrinol 2015;11:101-11.
3. Janeway KA, Kim SY, Lodish M, Nose V, Rustin P, Gaal J, et al. Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations. Proc Natl Acad Sci U S A 2011;108:314-8.
4. Vanharanta S, Buchta M, McWhinney SR, Virta SK, Peczkowska M, Morrison CD, et al. Early-onset renal cell carcinoma as a novel extraparaganglial component of SDHB-associated heritable paraganglioma. Am J Hum Genet 2004;74:153-9.
5. Baysal BE, Ferrell RE, Willett-Brozick JE, Lawrence EC, Myssiorek D, Bosch A, et al. Mutations inSDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science 2000;287:848-51.
6. Warburg O. Ueber den stoffwechsel der tumoren. Constable, London. 1930.
7. Tomlinson IP, Alam NA, Rowan AJ, Barclay E, Jaeger EE, Kelsell D, et al. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet 2002;30:406-10.
8. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, et al. IDH1 and IDH2 mutations in gliomas. N Eng J Med 2009;360:765-73.
9. Morin A, Letouze E, Gimenez-Roqueplo AP, Favier J. Oncometabolitesdriven tumorigenesis: From genetics to targeted therapy. Int J Cancer 2014;135:2237-48.
10. Gimenez-Roqueplo AP, Caumont-Prim A, Houzard C, Hignette C, Hernigou A,Halimi P, et al. Imaging work-up for screening of paragangliomaand pheochromocytoma in SDHx mutation carriers: a multicenter prospective study from the PGL.EVA Investigators. J Clin Endocrinol Metab 2013;98: E162-73.
11. Amar L, Baudin E, Burnichon N, Peyrard S, Silvera S, Bertherat J, et al. Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas. J Clin Endocrinol Metab 2007;92:3822-8.
12. Gimenez-Roqueplo AP, Favier J, Rustin P, Rieubland C, Crespin M, Nau V, et al.Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas. Cancer Res 2003;63:5615-21.
13. Letouze E, Martinelli C, Loriot C, Burnichon N, Abermil N, Ottolenghi C, et al. SDH mutations establish a hypermethylator phenotype in paraganglioma. Cancer Cell 2013;23:739-52.
14. Selak MA, Armour SM, MacKenzie ED, Boulahbel H, Watson DG, Mansfield KD, et al. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell 2005;7: 77-85.
15. Imperiale A, Moussallieh FM, Roche P, Battini S, Cicek AE, Sebag F, et al. Metabolome profiling by HRMAS NMR spectroscopy of pheochromocytomas and paragangliomas detects SDH deficiency: clinical and pathophysiological implications. Neoplasia 2015;17:55-65.
16. Korpershoek E, Favier J, Gaal J, Burnichon N, van Gessel B, Oudijk L, et al. SDHA immunohistochemistry detects germline SDHA gene mutations in apparently sporadic paragangliomas and pheochromocytomas. J Clin Endocrinol Metab 2011;96:E1472-6.
17. Lendvai N, Pawlosky R, Bullova P, Eisenhofer G, Patocs A, Veech RL, et al. Succinate-to-fumarate ratio as a new metabolic marker to detect the presence of SDHB/D-related paraganglioma: initial experimental and ex vivo findings. Endocrinology 2014;155:27-32.
18. Menara M, Oudijk L, Badoual C, Bertherat J, Lepoutre-Lussey C, Amar L, et al. SDHD immunohistochemistry: a new tool to validate SDHx mutations in pheochromocytoma/paraganglioma. J Clin Endocrinol Metab 2015;100:E287-91.
19. Rao JU, Engelke UF, Rodenburg RJ, Wevers RA, Pacak K, Eisenhofer G, et al. Genotype-specific abnormalities in mitochondrial function associate with distinct profiles of energy metabolism and catecholamine content in pheochromocytoma and paraganglioma. Clin Cancer Res 2013;19: 3787-95.
20. Rao JU, Engelke UF, Sweep FC, Pacak K, Kusters B, Goudswaard AG, et al. Genotype-specific differences in the tumor metabolite profile of pheochromocytoma and paraganglioma using untargeted and targeted metabolomics. J Clin Endocrinol Metab 2015;100:E214-22.
21. Richter S, Peitzsch M, Rapizzi E, Lenders JW, Qin N, de Cubas AA, et al. Krebs cycle metabolite profiling for identification and stratification of pheochromocytomas/paragangliomas due to succinate dehydrogenase deficiency. J Clin Endocrinol Metab 2014;99:3903-11.
22. van Nederveen FH,Gaal J, Favier J, Korpershoek E,Oldenburg RA, de Bruyn EM, et al. An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis. Lancet Oncol 2009;10:764-71.
23. Pollard PJ, Briere JJ, Alam NA, Barwell J, Barclay E, Wortham NC, et al. Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations. Hum Mol Genet 2005;14:2231-9.
24. Andronesi OC, Kim GS, Gerstner E, Batchelor T, Tzika AA, Fantin VR, et al. Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy. Sci Transl Med 2012;4:116ra4.
25. Choi C, Ganji SK, DeBerardinis RJ, Hatanpaa KJ, Rakheja D, Kovacs Z, et al. 2-hydroxyglutarate detection bymagnetic resonance spectroscopy in IDHmutated patients with gliomas. Nat Med 2012;18:624-9.
26. Elkhaled A, Jalbert LE, Phillips JJ, Yoshihara HA, Parvataneni R, Srinivasan R, et al. Magnetic resonance of 2-hydroxyglutarate in IDH1-mutated lowgrade gliomas. Sci Translat Med 2012;4:116ra5.
27. Harada K, Honmou O, Liu H, Bando M, Houkin K, Kocsis JD. Magnetic resonance lactate and lipid signals in rat brain after middle cerebral artery occlusion model. Brain Res 2007;1134:206-13.
28. Burnichon N, Vescovo L, Amar L, Libe R, de Reynies A, Venisse A, et al. Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paraganglioma. Hum Mol Genet 2011;20:3974-85.
29. Webb PG, Sailasuta N, Kohler SJ, Raidy T, Moats RA, Hurd RE. Automated single-voxel proton MRS: technical development and multisite verification. Magn Reson Med 1994;31:365-73.
30. Agarwal M, Chawla S, Husain N, Jaggi RS, Husain M, Gupta RK. Higher succinate than acetate levels differentiate cerebral degenerating cysticerci from anaerobic abscesses on in-vivo proton MR spectroscopy. Neuroradiology 2004;46:211-5.
31. Rustin P, Chretien D, Bourgeron T, Gerard B, Rotig A, Saudubray JM, et al. Biochemical and molecular investigations in respiratory chain deficiencies. Clin Chim Acta 1994;228:35-51.
32. Oudijk L, Gaal J, Korpershoek E, van Nederveen FH, Kelly L, Schiavon G, et al. SDHA mutations in adult and pediatric wild-type gastrointestinal stromal tumors. Mod Pathol 2013;26:456-63.
33. Varoquaux A, le Fur Y, Imperiale A, Reyre A, Montava M, Fakhry N, et al. Magnetic resonance spectroscopy of paragangliomas: new insights into in vivo metabolomics. Endocr Relat Cancer 2015;22: M1-8.
34. Gonias S, Goldsby R, Matthay KK, Hawkins R, Price D, Huberty J, et al. Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma. J Clin Oncol 2009;27:4162-8.
35. Jimenez C, Rohren E, Habra MA, Rich T, Jimenez P, Ayala-Ramirez M, et al. Current and future treatments for malignant pheochromocytoma and sympathetic paraganglioma. Curr Oncol Rep 2013;15: 356-71.
36. Hadoux J, Favier J, Scoazec JY, Leboulleux S, AlGhuzlan A, Caramella C, et al. SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma. Int J Cancer 2014;135:2711-20.
37. Xekouki P, Szarek E, Bullova P, Giubellino A, Quezado M, Mastroyannis SA, et al. Pituitary adenoma with paraganglioma/pheochromocytoma (3PAs) and succinate dehydrogenase defects in human and mice. J Clin Endocrinol Metab 2015:jc20144297.
38. Imperiale A, Battini S,AverousG, Mutter D, Goichot B, Bachellier P, et al. In vivo detection of catecholamines by magnetic resonance spectroscopy: a potential specific biomarker for the diagnosis of pheochromocytoma. Surgery. 2015 May 1. [Epub ahead of print].